Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors
September 19 2017 - 7:00AM
Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage
biotechnology company developing novel hospital-based therapies for
the management of acute, life-threatening conditions, today
announced the appointment of pharmaceutical industry leader
Rosemary A. (Rose) Crane to Edge’s Board of Directors. Ms. Crane’s
appointment expands the Board of Directors to 10 members, eight of
whom are independent.
“With over 30 years of experience in global commercialization
and business operations in the pharmaceutical and life science
industry, and more than 25 years of therapeutic and drug launch
experience, Rose brings a wealth of expertise that complements and
strengthens our existing Board of Directors skill-set, and will
make her a vital contributor in guiding our growth strategy,” said
Sol J. Barer, Ph.D., Edge’s Chairman of the Board.
Ms. Crane currently serves as a Director of Teva Pharmaceuticals
and as Vice Chairman of the Board of Zealand Pharma A/S. Ms. Crane
held senior executive positions at Johnson & Johnson, including
Group Chairman, OTC & Nutritional Group, Group Chairman,
Consumer, Specialty Pharmaceuticals and Nutritionals, and Executive
Vice President of Global Marketing for the Pharmaceutical Group.
Ms. Crane has also served in executive roles at Bristol-Myers
Squibb, including President of U.S. Primary Care and President of
Global Marketing and Consumer Products. She also served as
President and Chief Executive Officer of MELA Sciences, Inc. and
President and Chief Executive Officer of Epocrates, Inc. Ms. Crane
received her MBA from Kent State University and her BA in
Communications and English from the State University of New
York.
Ms. Crane commented, “Edge expects to reach key milestones
during the balance of 2017 and in 2018. The team’s progress with
its lead development program, EG-1962, has been impressive, and
serving on Edge’s Board of Directors is a great opportunity for me
to share my commercial launch experience with Edge’s Board and
management team to move the company ahead.”
About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology
company that discovers, develops and seeks to commercialize novel,
hospital-based therapies capable of transforming treatment
paradigms for the management of acute, life-threatening
neurological and other conditions. EG-1962, Edge’s lead product
candidate, has the potential to fundamentally improve patient
outcomes and transform the management of aneurysmal subarachnoid
hemorrhage, which is bleeding around the brain due to a ruptured
brain aneurysm. Edge is evaluating EG-1962 in two clinical studies:
a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via external
ventricular drain, and a study of direct intracisternal
administration of EG-1962. For additional information about Edge,
please visit www.edgetherapeutics.com.
Forward-Looking Statements
This press release and any statements of representatives of Edge
Therapeutics, Inc. related thereto that are not historical in
nature contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements may include, without limitation, statements with respect
to Edge’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," “seeks,” "intends," "plans,"
"potential" or similar expressions, including statements with
respect to the potential effects of its products, and the timing of
key milestones. These statements are based upon the current beliefs
and expectations of Edge’s management and are subject to
significant risks and uncertainties. Actual results may differ
significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks
and uncertainties that are subject to change based on various risk
factors (many of which are beyond Edge's control) as described
under the heading "Risk Factors" in Edge’s filings with the United
States Securities and Exchange Commission.
Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208 EDGE (3343)
Email: ggin@edgetherapeutics.com
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jul 2023 to Jul 2024